NCT02531516 2026-04-13An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASAragon Pharmaceuticals, Inc.Phase 3 Active not recruiting1,503 enrolled